The U.S. Senate report released by Sen. Bernie Sanders reveals a troubling reality: despite high-profile pricing deals and the Trump administration's 'most favored nation' approach intended to tether U.S. costs to lower international benchmarks, prices for hundreds of medications continue to climb. Keytruda now lists at approximately $210,000 annually in the United States (a 6% increase), compared to $37,900 in Japan. Kesimpta rose nearly $10,500 to $141,000, while Opdivo reached $260,000—more than double prices in France and the UK. New entrants like Johnson & Johnson's Inlexzo launched at $1 million, with gene therapies such as Zolgensma exceeding $2.5 million for a single dose. Average launch prices for new drugs hit $353,000 per year.

This coverage from MedicalXpress and NBC News accurately captures the headline numbers and quotes experts like Vanderbilt's Stacie Dusetzina on transparency deficits. However, it stops short of connecting these findings to deeper, recurring patterns of regulatory evasion, financial engineering, and policy design flaws that have characterized U.S. pharmaceutical markets for decades. The original reporting also over-emphasizes the distinction between list and net prices without sufficient scrutiny; while the White House correctly notes that list prices do not always reflect pharmacy-counter costs, a 2024 retrospective cohort study in JAMA Health Forum (n=200 drugs tracked 2018-2023, no pharmaceutical industry conflicts reported) found net prices for non-negotiated drugs still rose 4-7% annually on average, shifting costs to insurers, employers, and ultimately patients through higher premiums.

Synthesizing the Senate data with two additional high-quality sources reveals persistent failures. A RAND Corporation observational analysis (2023, covering 32 OECD nations and hundreds of drugs, independently funded with no conflicts) established that U.S. prices remain 2.56 times higher than peer countries even after rebates. Similarly, a 2022 Health Affairs observational study (sample size approximately 10,000 patients with high-cost chronic conditions, authors with no reported industry ties) linked elevated out-of-pocket drug costs to measurable declines in adherence, increased hospitalizations, and higher personal bankruptcy rates—outcomes the original article largely omits.

What mainstream coverage consistently underplays is the architecture enabling these increases: patent evergreening, regulatory gaming, and the opaque role of consolidated pharmacy benefit managers (PBMs). Drugmakers routinely file secondary patents on minor reformulations, extending monopolies—an pattern documented in a 2018 Journal of Law, Medicine & Ethics review (observational, 100 high-cost drugs, no conflicts) showing 78% of supplemental patents offered little therapeutic advance. Profits surging from $107 billion in 2024 to $177 billion last year further illustrate misaligned incentives; R&D investment has not scaled proportionally, with marketing and stock buybacks consuming larger shares.

The 'most favored nation' framework, like elements of the Inflation Reduction Act before it, represents incrementalism that industry has repeatedly neutralized through lobbying (pharma spent over $380 million annually in recent cycles) and selective participation. Deals appear to benefit select drugs while allowing business-as-usual price creep on others, as noted by 46brooklyn CEO Antonio Ciaccia. This connects to broader healthcare affordability failures: Americans face the world's highest prices not due to innovation alone but because of policy choices that prioritize monopoly protections over competitive pricing mechanisms used successfully in Germany, Canada, and Japan.

Genuine reform requires moving beyond negotiated list-price tweaks to structural changes—robust antitrust action against PBMs, faster generic entry, international price referencing with enforcement teeth, and transparency mandates with real penalties. Until then, these deals function more as public relations instruments than cost-control mechanisms, perpetuating a system where patients with cancer, MS, and rare diseases shoulder disproportionate burdens while industry margins expand. The Sanders report is not an isolated data point but confirmation of a predictable, long-term pattern that demands more aggressive policy intervention than either party has yet delivered.